EA200601461A1 - NEW DERIVATIVES BENZIL (IDEN) LACTAM - Google Patents
NEW DERIVATIVES BENZIL (IDEN) LACTAMInfo
- Publication number
- EA200601461A1 EA200601461A1 EA200601461A EA200601461A EA200601461A1 EA 200601461 A1 EA200601461 A1 EA 200601461A1 EA 200601461 A EA200601461 A EA 200601461A EA 200601461 A EA200601461 A EA 200601461A EA 200601461 A1 EA200601461 A1 EA 200601461A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lactam
- benzil
- iden
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Настоящее изобретение относится к новым производным бензил(иден)лактама, соединениям формулы I, где Rпредставляет собой группу формулы Gили G, изображенной ниже, где R, R, R, R, X, а, n и m являются такими, как определено здесь, их фармацевтически приемлемым солям и фармацевтическим композициям, которые включают в себя селективные антагонисты, обратные агонисты и частичные агонисты серотониновых рецепторов 1 (5-HT), а именно одного или обоих 5-HTи 5-HTрецепторов. Соединения по изобретению являются полезными в лечении или предупреждении депрессии, тревоги, обсессивно-компульсивного расстройства (OCD) и других расстройств, при которых показан агонист или антагонист 5-HT, и имеют сниженный потенциал сердечных побочных эффектов, в частности пролонгирования QTc.The present invention relates to new benzyl (Eden) lactam derivatives, compounds of the formula I, wherein R is a group of the formula G or G shown below, where R, R, R, R, X, a, n and m are as defined herein, their pharmaceutically acceptable salts and pharmaceutical compositions, which include selective antagonists, inverse agonists and partial agonists of serotonin receptors 1 (5-HT), namely one or both 5-HT and 5-HT receptors. The compounds of the invention are useful in the treatment or prevention of depression, anxiety, obsessive-compulsive disorder (OCD) and other disorders in which a 5-HT agonist or antagonist is indicated and have a reduced potential for cardiac side effects, in particular QTc prolongation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55380804P | 2004-03-17 | 2004-03-17 | |
PCT/IB2005/000583 WO2005090300A1 (en) | 2004-03-17 | 2005-03-07 | Novel benzyl(idene)-lactam derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200601461A1 true EA200601461A1 (en) | 2007-02-27 |
Family
ID=34960867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200601461A EA200601461A1 (en) | 2004-03-17 | 2005-03-07 | NEW DERIVATIVES BENZIL (IDEN) LACTAM |
Country Status (29)
Country | Link |
---|---|
US (1) | US7479559B2 (en) |
EP (1) | EP1727794B1 (en) |
JP (1) | JP4880583B2 (en) |
KR (1) | KR20060124770A (en) |
CN (1) | CN1934081A (en) |
AP (1) | AP2006003726A0 (en) |
AR (1) | AR050403A1 (en) |
AT (1) | ATE533745T1 (en) |
AU (1) | AU2005223481A1 (en) |
BR (1) | BRPI0508825A (en) |
CA (1) | CA2559530C (en) |
CR (1) | CR8618A (en) |
DO (1) | DOP2005000035A (en) |
EA (1) | EA200601461A1 (en) |
EC (1) | ECSP066853A (en) |
ES (1) | ES2374629T3 (en) |
GT (1) | GT200500051A (en) |
IL (1) | IL178105A0 (en) |
MA (1) | MA28474B1 (en) |
NL (1) | NL1028558C2 (en) |
NO (1) | NO20063602L (en) |
PA (1) | PA8626501A1 (en) |
PE (1) | PE20051153A1 (en) |
SV (1) | SV2005002051A (en) |
TN (1) | TNSN06287A1 (en) |
TW (1) | TW200604165A (en) |
UY (1) | UY28811A1 (en) |
WO (1) | WO2005090300A1 (en) |
ZA (1) | ZA200607133B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1836164B1 (en) * | 2005-01-13 | 2011-08-24 | GE Healthcare Limited | 11c-labeled benzyl-lactam compounds and their use as imaging agents |
CA2612268A1 (en) * | 2005-06-17 | 2006-12-28 | Pfizer Products Inc. | Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists |
WO2007026219A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
WO2008068614A2 (en) * | 2006-12-06 | 2008-06-12 | Pfizer Products Inc. | Stereoselective synthesis of 1-[6-ethyl-1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one |
FR2948660B1 (en) * | 2009-07-30 | 2011-08-19 | Oroxcell | 2-AMINO-2-PHENYL-ALKANOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
WO2011075784A1 (en) * | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
WO2014028829A1 (en) | 2012-08-16 | 2014-02-20 | The Scripps Research Institute | Novel kappa opioid ligands |
JP6440625B2 (en) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Methods and compositions for treating schizophrenia |
JP6321825B2 (en) * | 2014-01-20 | 2018-05-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders |
TW201706265A (en) | 2015-03-09 | 2017-02-16 | 必治妥美雅史谷比公司 | Lactams as inhibitors of ROCK |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58189163A (en) * | 1982-04-02 | 1983-11-04 | Takeda Chem Ind Ltd | Condensed pyrrolinone derivative |
IL106142A (en) | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
EP0689536B1 (en) | 1993-03-16 | 2001-05-23 | Pfizer Inc. | Naphthalene derivatives |
JP3786983B2 (en) * | 1994-01-27 | 2006-06-21 | シエーリング アクチエンゲゼルシャフト | Pyrrolidinone derivative |
GB9410512D0 (en) | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
DK0767782T3 (en) | 1994-06-29 | 2002-02-18 | Pfizer | Aryl and heteroarylalkoxynaphthalane derivatives |
WO1997036867A1 (en) * | 1996-03-29 | 1997-10-09 | Pfizer Inc. | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
UA56185C2 (en) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method |
DE10002509A1 (en) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
-
2005
- 2005-03-07 AT AT05708687T patent/ATE533745T1/en active
- 2005-03-07 AP AP2006003726A patent/AP2006003726A0/en unknown
- 2005-03-07 BR BRPI0508825-9A patent/BRPI0508825A/en not_active IP Right Cessation
- 2005-03-07 CN CNA2005800085634A patent/CN1934081A/en active Pending
- 2005-03-07 WO PCT/IB2005/000583 patent/WO2005090300A1/en active Application Filing
- 2005-03-07 ES ES05708687T patent/ES2374629T3/en active Active
- 2005-03-07 KR KR1020067019078A patent/KR20060124770A/en not_active Application Discontinuation
- 2005-03-07 AU AU2005223481A patent/AU2005223481A1/en not_active Abandoned
- 2005-03-07 EP EP05708687A patent/EP1727794B1/en active Active
- 2005-03-07 CA CA2559530A patent/CA2559530C/en not_active Expired - Fee Related
- 2005-03-07 EA EA200601461A patent/EA200601461A1/en unknown
- 2005-03-07 JP JP2007503427A patent/JP4880583B2/en not_active Expired - Fee Related
- 2005-03-10 DO DO2005000035A patent/DOP2005000035A/en unknown
- 2005-03-15 UY UY28811A patent/UY28811A1/en not_active Application Discontinuation
- 2005-03-15 GT GT200500051A patent/GT200500051A/en unknown
- 2005-03-15 PE PE2005000296A patent/PE20051153A1/en not_active Application Discontinuation
- 2005-03-15 TW TW094107893A patent/TW200604165A/en unknown
- 2005-03-16 AR ARP050101025A patent/AR050403A1/en unknown
- 2005-03-16 NL NL1028558A patent/NL1028558C2/en not_active IP Right Cessation
- 2005-03-16 SV SV2005002051A patent/SV2005002051A/en not_active Application Discontinuation
- 2005-03-17 US US11/083,188 patent/US7479559B2/en not_active Expired - Fee Related
- 2005-03-17 PA PA20058626501A patent/PA8626501A1/en unknown
-
2006
- 2006-08-09 NO NO20063602A patent/NO20063602L/en not_active Application Discontinuation
- 2006-08-25 ZA ZA200607133A patent/ZA200607133B/en unknown
- 2006-09-13 CR CR8618A patent/CR8618A/en not_active Application Discontinuation
- 2006-09-14 IL IL178105A patent/IL178105A0/en unknown
- 2006-09-15 MA MA29327A patent/MA28474B1/en unknown
- 2006-09-15 EC EC2006006853A patent/ECSP066853A/en unknown
- 2006-09-15 TN TNP2006000287A patent/TNSN06287A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20050245521A1 (en) | 2005-11-03 |
UY28811A1 (en) | 2005-10-31 |
ECSP066853A (en) | 2006-11-24 |
EP1727794A1 (en) | 2006-12-06 |
PE20051153A1 (en) | 2006-01-28 |
ATE533745T1 (en) | 2011-12-15 |
US7479559B2 (en) | 2009-01-20 |
NL1028558A1 (en) | 2005-09-20 |
AR050403A1 (en) | 2006-10-25 |
GT200500051A (en) | 2005-10-24 |
CN1934081A (en) | 2007-03-21 |
DOP2005000035A (en) | 2005-10-31 |
CR8618A (en) | 2006-11-15 |
SV2005002051A (en) | 2005-12-13 |
EP1727794B1 (en) | 2011-11-16 |
JP4880583B2 (en) | 2012-02-22 |
CA2559530C (en) | 2012-04-24 |
NO20063602L (en) | 2006-09-08 |
TW200604165A (en) | 2006-02-01 |
PA8626501A1 (en) | 2005-11-25 |
CA2559530A1 (en) | 2005-09-29 |
AP2006003726A0 (en) | 2006-10-31 |
TNSN06287A1 (en) | 2007-12-03 |
BRPI0508825A (en) | 2007-08-14 |
JP2007529495A (en) | 2007-10-25 |
KR20060124770A (en) | 2006-12-05 |
MA28474B1 (en) | 2007-03-01 |
ZA200607133B (en) | 2007-12-27 |
IL178105A0 (en) | 2006-12-31 |
AU2005223481A1 (en) | 2005-09-29 |
ES2374629T3 (en) | 2012-02-20 |
NL1028558C2 (en) | 2006-06-27 |
WO2005090300A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200601461A1 (en) | NEW DERIVATIVES BENZIL (IDEN) LACTAM | |
DE602004021921D1 (en) | AZABICYCLOALKAN COMPOUNDS AS MUSCARIN RECEPTOR ANTAGONISTS | |
EA200600811A1 (en) | NEW TETRAHYDROSPIRO {PIPERIDIN-2,7'-PYRROLO [3,2-b] PYRIDINE} DERIVATIVES AND NEW INDOLA DERIVATIVES, APPLICATION FOR THE TREATMENT OF DISORDERS RELATED TO 5-HT-RECEPTOR | |
ATE445609T1 (en) | SUBSTITUTED THIOPHEN DERIVATIVES AS GLUCAGONE RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC APPLICATIONS | |
IS8502A (en) | Azate cyclic heterocycles as cannabinoid receptor antagonists | |
EA200701583A1 (en) | HETEROCYCLIC TETRACYCLIC DERIVATIVES OF HYDROFURANE AS 5HT2 INHIBITORS IN THERAPY OF CNS DISORDERS | |
EA200100748A1 (en) | MONOAMINE RETURN INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | |
NO20080670L (en) | Substituted piperazines as metabotrophic glutamate receptor antagonists | |
DK1735278T3 (en) | Histamine H3 receptor agents, preparation and therapeutic applications | |
ATE289593T1 (en) | SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDE AS GABA BRAIN RECEPTOR LIGANDS | |
MX2012004848A (en) | Tricyclic heterocyclic compounds. | |
KR970701544A (en) | Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists | |
EA200702612A1 (en) | COMPOUNDS OF BENZIMIDAZOZOLKARBOXAMIDE AS AGONISTS OF 5-HT RECEPTORS | |
CY1109694T1 (en) | Pyrrolidine derivatives as H3 histamine receptor antagonists | |
NO20060191L (en) | 1- (alkylaminoalkyl-pyrolidine / piperidinyl) 2,2-diphenylacetamide derivatives as muscarinic receptor agonists | |
DE602004005960D1 (en) | HETEROARYL-SUBSTITUTED PYRROLÄ2, 3-BÜPYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | |
EA200701758A1 (en) | REPLACED ARYL DERIVATIVES 1,4-PYRAZINE | |
NO20080671L (en) | Bicyclic piperazines as metabotrophic glutamate receptor antagonists | |
WO2005113535A3 (en) | Pyrazinylmethyl lactam derivatives | |
BRPI0410237A (en) | methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
BRPI0510564A (en) | pharmaceutically acceptable compounds and tautomers, stereoisomers, and salts thereof, pharmaceutical compositions, method for preparing pharmaceutical compositions, and use of a compound | |
EA200801639A1 (en) | DERIVATIVES AREA | |
ATE388150T1 (en) | CRF RECEPTOR ANTAGONISTS AND RELATED METHODS | |
Sanchez | Allosteric modulation of monoamine transporters–new drug targets in depression | |
SE0400968D0 (en) | Aryl glycine ether derivatives and their use |